Sentence examples for based assays can be from inspiring English sources
The ageing population world wide will generate more patients who expect health services to provide fast and accurate diagnostic tools mass spectrometry based assays can be expected to play a major role in tomorrows hospital laboratories.
These examples highlight that although activity based assays can be biased toward identifying ATP-noncompetitive inhibitors, the discovery of substrate phosphorylation site inhibitors from such assays remains elusive.
Assuming that all 11 of the GO categorised genes are capable of inducing apoptosis when over-expressed, the false negative rate of the array based assay can be estimated as 91%.
To see how the estimated relative mobilities correlate to the actual relative mobilities for the small molecules listed in Table 1 and further prove that this electrophoresis based assay can be applied to these small molecules, we sulfated corresponding small molecule substrates using SULT1A1, SULT1E1, SULT2A1 and CHST4, and then separated the reactions on an 8% SDS gel.
Plate-based assays can be used for high-content screening of cell populations [3] or to capture detailed cell morphology and state information [4] – in fact a number of dedicated commercial platforms are on the market [5] – but these latter applications come at a high reagent cost relative to miniaturized assays.
Tissue slide-based assays can be more cost effective in screening the expression of selected miRNAs (n < 10) in a large number of tissue samples (n > 500) using tissue microarrays, whereas RT-PCR assays provide high throughput in terms of the number of independent miRNAs (n > 100) that can be detected in a single tube reaction.
Although such assays are routinely used to find novel small chemical inhibitors in the pharmaceutical industry, we tested whether such mechanistically based screening assays can be used to rapidly provide information on the potential for compounds to produce specific biological toxic effects that would identify those requiring further in-depth study.
And, for the first time, the molecular endpoints were quantitatively correlated to phenotypic endpoints and generally consistent with those based on conventional in vitro and in vivo genotoxicity assays, suggesting that the toxicogenomics-based assays can be promising for potential genotoxicity assessment of ENMs.
As we have demonstrated, selection of clinical candidates based on activity profiles from in vitro kinase assays can be misleading.
These assays can be normalised by cell counts based on GAPDH qPCR results for use in PBMC.
